Eli Lilly confirms weight loss approval with list price of $1,059.87

Eli Lilly (LLY) confirmed the Food and Drug Administration approved the company’s Zepbound injection. Zepbound is indicated for adults with obesity or those who are overweight and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off, the company said in a statement. “It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis,” Eli Lilly added. Zepbound is expected to be available in the U.S. by the end of the year in six doses at a list price of $1,059.87, which Eli Lilly says is approximately 20% lower than Novo Nordisk’s (NVO) semaglutide 2.4 mg injection for weight loss.